Pharmacovigilance (PV) inspection should begin even before a health authority plans a visit. Inspection readiness relies heavily on an existing quality system, accurate and periodic documentation, and clear ownership of safety responsibilities throughout the organization.
Read MoreDeveloping a global regulatory strategy for a new drug means planning early for the markets you want to enter. It involves gathering the evidence each region expects and the submission sequence to reduce delays. A
Read MoreRegulatory inspections can feel unpredictable, but most findings follow similar tendencies across FDA, EMA, and DCGI reviews. A strong FDA inspection-readiness mindset is not about preparing for one visit; it is about building a system
Read MoreAccelerated approval pathways are designed to bring important therapies to patients sooner, especially in serious or life-threatening diseases with unmet medical needs. For a regulatory service provider, the key value is helping sponsors choose the
Read More
Regulatory affairs has never exactly been a slow moving field. But 2026 feels different. Agencies that spent years cautiously watching AI from a distance are now actively deploying it. Real world evidence once a nice
Read More
Germany is Europe’s largest pharma market with strict regulations. Learn how Vigilare helps companies navigate BfArM, EMA, and EU compliance with speed and clarity.
Read More
Medical device labelling is more than just a regulatory requirement—it’s a critical communication tool that ensures safety, usability, and compliance. Whether you’re a manufacturer, distributor, or healthcare provider, understanding the essential elements of clear and
Read More
From Vigilare Biopharma: The recent PRAC meeting (2-5 June 2025) underscores the relentless pace of pharmacovigilance evolution. From gene therapy safety to AI integration and refined risk management for established classes, the demands on sponsors
Read More
The Evolving Pharma Landscape: Innovation Demands AgilityThe pharmaceutical industry is a dynamic ecosystem where innovation never sleeps. From advancements in manufacturing technologies to shifts in formulation strategies, post-approval changes are inevitable. Yet, every modification—whether to
Read MoreIs your clinical trial ready for ICH E6 (R3)? Discover the key areas to focus on, from risk-based quality management to digital transformation, and ensure compliance with the latest GCP guidelines.
Read More